Group items tagged

The NHS claims that it's been able to save taxpayers £1.2 billion in just three years by procuring hundreds of hospital medicines at a better price. The adoption of cheaper versions of a single drug - adalimumab - which is used to treat more than 45,000 patients with rheumatoid arthritis, inflammatory bowel disease and psoriasis, has accounted for about one third of the savings. After the exclusive patent on the drug - originally known as its brand name Humira - expired in 2018, the NHS struck cost-saving deals to bulk-buy generic versions, which have the same quality, safety and efficacy of a branded one. Since then, tens of millions of pounds have been saved by buying cheaper generic versions of other medicines for conditions ranging from severe skin infections to aggressive blood cancers. Four in five medicines prescribed in the NHS are now non-branded, helping the NHS to achieve significant savings while ensuring the continuity of high-quality patient care. NHS chief executive Amanda Pritchard said: "Smart deals by the NHS mean patients are getting the best medicines and taxpayers are getting best value.

Sclerotherapy Training Courses for Physicians and Nurses is organized by Empire Medical Training and will be held on Jul 08, 2022 at New York Marriott at the Brooklyn Bridge, New York City, New York, United States of America

Britain's GlaxoSmithKline will receive $1.25 billion (about £921 million) from Gilead Sciences as part of a settlement between its HIV medicines unit and the US-based drugmaker, ending a long-drawn patent dispute. The settlement, announced by GSK on Tuesday (February 1), relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds. HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm. The payment is expected to be made in the first quarter this year, London-listed GSK said. Gilead will also pay a 3 per cent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.

Rowlands pharmacy has launched a new weight management service across its UK network, challenging perceptions around weight loss and providing expert support to those in need. The launch comprises a pilot roll-out across 100 Rowlands branches to increase consideration of pharmacies for weight management-based advice. Commenting on the launch, Nigel Swift, managing director of Rowlands, said: "One of the biggest challenges facing many adults looking to address any weight concerns is knowing where and how to start. Our new weight management service is designed to help all those setting out on a new weight loss journey but also those who have struggled to find a plan that works for them." "Our pharmacy teams offer comprehensive healthcare advice and a variety of weight management products with a friendly approach that naturally puts customers at ease, and we're looking forward to welcoming all those looking to take their first step with us."